How much cash does Altimmune generate?

Altimmune (ALT) generated -$71.6M in operating cash flow over the trailing twelve months.

What is Altimmune's free cash flow?

After $111.0K of capital expenditures, Altimmune's free cash flow was -$68.8M over the trailing twelve months, up 10.2% year over year.

Where does Altimmune's cash flow data come from?

Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Altimmune ALT Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$91.08M-3.4%	-$88.09M-5.0%	-$83.92M+4.4%	-$87.75M+2.8%	-$90.24M+5.1%
Depreciation and amortization	$106K-5.4%	$112K-5.9%	$119K-7.8%	$129K-19.4%	$160K-32.8%
Stock-based compensation	$15.44M-4.0%	$16.08M+11.0%	$14.49M+3.4%	$14.01M-5.0%	$14.76M+2.5%
Deferred income taxes	——	——	——	——	——
Amortization of debt issuance costs	——	——	——	——	——
Impairment charges	——	——	——	——	——
Change in accounts receivable	$1.16M+71.6%	$675K—	——	——	——
Change in accounts payable	——	——	——	——	-$2.68M-44.3%
Change in accrued liabilities	$1.6M-33.2%	$2.39M—	——	——	——
Change in other assets	——	——	$1.11M+27.0%	$874K+247%	-$593K+88.3%
Net cash from operating activities	-$71.64M-6.1%	-$67.54M-1.8%	-$66.35M+18.7%	-$81.57M-1.5%	-$80.33M-0.6%
Capital expenditures	——	——	——	——	——
Purchases of investments	$285.6M+0.1%	$285.45M+35.9%	$210.11M+143%	$86.59M-17.8%	$105.35M-9.0%
Proceeds from maturities/sales of investments	$154.57M+1.0%	$152.99M-10.2%	$170.43M-13.7%	$197.43M+77.3%	$111.39M+27.5%
Net cash from investing activities	-$131.06M+1.1%	-$132.47M—	——	——	——
Proceeds from issuance of common stock	$147.73M-15.0%	$173.73M+42.7%	$121.74M+47.8%	$82.36M+84.1%	$44.73M+348%
Taxes paid for net share settlement	$726K+2.4%	$709K+3.4%	$686K-0.6%	$690K-25.6%	$928K+9.2%
Other financing activities	——	——	——	——	——
Net cash from financing activities	$251.2M+21.4%	$206.84M+52.3%	$135.8M+40.4%	$96.71M+118%	$44.42M+342%
Effect of exchange rate changes on cash	-$329K-106%	-$160K-16,100%	$1K-99.0%	$99K+39.4%	$71K+47.9%
Net increase (decrease) in cash	——	——	——	$120.53M+441%	-$35.33M+65.9%
Interest paid	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$2.41M+8.3%	$2.22M+4.3%	$2.13M-26.9%	$2.92M-18.0%	$3.55M-7.7%
Non-cash interest expense	——	——	——	——	——
Depreciation	$106K-5.4%	$112K-5.9%	$119K-7.8%	$129K-19.4%	$160K-32.8%
Impairment of assets held for sale	——	——	——	——	——
Accrued expenses and other liabilities	$1.6M-33.2%	$2.39M—	——	——	——
Increase Decrease In Income Taxes And Tax Incentive Receivable	-$1.96M+28.5%	-$2.74M+10.2%	-$3.05M—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$1.11M+27.0%	$874K+247%	-$593K+88.3%
Proceeds From Sale And Maturity Of Available For Sale Securities	$154.57M+1.0%	$152.99M-10.2%	$170.43M-13.7%	$197.43M+77.3%	$111.39M+27.5%
Payments Of Deferred Offering Costs	$402K-8.2%	$438K—	——	——	——
Proceeds From Issuance Of Common Stock And Pre Funded Warrants Direct Offering Net	——	——	——	——	——
Other, net	——	——	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	——
Deferred Offering Costs In Accrued Expenses And Other Current Liabilities	——	——	——	——	——
Free cash flow	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Altimmune.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Altimmune generate?: Altimmune (ALT) generated -$71.6M in operating cash flow over the trailing twelve months.
What is Altimmune's free cash flow?: After $111.0K of capital expenditures, Altimmune's free cash flow was -$68.8M over the trailing twelve months, up 10.2% year over year.
Where does Altimmune's cash flow data come from?: Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.